Alterity Therapeutics Completes 1-for-50 Capital Consolidation

On June 12, 2026, Alterity Therapeutics Limited announced the completion of a consolidation of its issued capital, commonly referred to as a reverse stock split. The consolidation was executed on a fifty (50) to one (1) basis, following shareholder approval at a General Meeting held on May 29, 2026. As a result of this corporate action, the company's post-consolidation capital structure now consists of 217,508,862 ordinary fully paid shares. Additionally, various series of quoted and unquoted options were adjusted accordingly. Fractional entitlements resulting from the consolidation were rounded up to the nearest whole number. Normal trading on a T+2 settlement basis commenced on the ASX under the code 'ATH' on the date of the announcement. Alterity continues to focus on its clinical-stage pipeline, specifically ATH434 for the treatment of Multiple System Atrophy (MSA), and is preparing for a Phase 3 pivotal trial.